JP2021501790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501790A5 JP2021501790A5 JP2020524870A JP2020524870A JP2021501790A5 JP 2021501790 A5 JP2021501790 A5 JP 2021501790A5 JP 2020524870 A JP2020524870 A JP 2020524870A JP 2020524870 A JP2020524870 A JP 2020524870A JP 2021501790 A5 JP2021501790 A5 JP 2021501790A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- halo
- independently
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 94
- 150000001875 compounds Chemical class 0.000 claims description 71
- 208000017169 kidney disease Diseases 0.000 claims description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- 201000010099 disease Diseases 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 13
- 208000016354 hearing loss disease Diseases 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000012268 mitochondrial disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- -1 wherein Chemical group 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 208000030533 eye disease Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- OGBAQIDQMBHMAQ-UHFFFAOYSA-N bromo-chloro-fluoro-lambda3-iodane Chemical group FI(Cl)Br OGBAQIDQMBHMAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 208000017445 musculoskeletal system disease Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 description 52
- 0 C*Cc1ccc(*C)nc1 Chemical compound C*Cc1ccc(*C)nc1 0.000 description 15
- 201000006938 muscular dystrophy Diseases 0.000 description 15
- 208000009304 Acute Kidney Injury Diseases 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 230000002485 urinary effect Effects 0.000 description 11
- 210000001635 urinary tract Anatomy 0.000 description 11
- 208000002903 Thalassemia Diseases 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 206010018364 Glomerulonephritis Diseases 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- 206010047115 Vasculitis Diseases 0.000 description 9
- 206010011878 Deafness Diseases 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 7
- 231100000895 deafness Toxicity 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 208000022461 Glomerular disease Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000008383 nephritis Diseases 0.000 description 6
- 210000005239 tubule Anatomy 0.000 description 6
- 206010058314 Dysplasia Diseases 0.000 description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 206010046851 Uveitis Diseases 0.000 description 5
- 208000005980 beta thalassemia Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 208000026292 Cystic Kidney disease Diseases 0.000 description 4
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 3
- 241000519995 Stachys sylvatica Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000003890 fistula Effects 0.000 description 3
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 208000009928 nephrosis Diseases 0.000 description 3
- 231100001027 nephrosis Toxicity 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 208000021090 palsy Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000008359 toxicosis Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- CONVAEXWACQJSA-UHFFFAOYSA-N 3-oxabicyclo[2.2.2]octane Chemical compound C1CC2CCC1OC2 CONVAEXWACQJSA-UHFFFAOYSA-N 0.000 description 2
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 108700037006 Adenine phosphoribosyltransferase deficiency Proteins 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000005024 Castleman disease Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- 206010011777 Cystinosis Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 208000029663 Hypophosphatemia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010053869 POEMS syndrome Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100036901 SLC2A4 regulator Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 102000018614 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 201000006288 alpha thalassemia Diseases 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 231100000852 glomerular disease Toxicity 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 201000011200 hepatorenal syndrome Diseases 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010072609 Adenine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000027580 BK-virus nephropathy Diseases 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 208000004884 Balkan Nephropathy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010062656 Bladder tamponade Diseases 0.000 description 1
- 241000181212 Bourbon virus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000023635 C1q nephropathy Diseases 0.000 description 1
- 201000005965 CAKUT Diseases 0.000 description 1
- LQWWPJOATMFTTM-UHFFFAOYSA-N CC1=CC=C=C(C)N=N1 Chemical compound CC1=CC=C=C(C)N=N1 LQWWPJOATMFTTM-UHFFFAOYSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007246 Carboxyhaemoglobinaemia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 208000034103 Castleman-Kojima disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1nccnc1 Chemical compound Cc1nccnc1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 206010011796 Cystitis interstitial Diseases 0.000 description 1
- 241000271305 Daphne laureola Species 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010011882 Deafness congenital Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000024940 Dent disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 208000004132 Diffuse mesangial sclerosis Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 201000004315 EAST syndrome Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000035751 Epidemic nephropathy Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
- 201000006328 Fanconi syndrome Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000033431 Finnish type congenital nephrotic syndrome Diseases 0.000 description 1
- 208000010006 Fraser Syndrome Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 208000009432 Galloway-Mowat syndrome Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000006004 Gitelman syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000033509 HANAC syndrome Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010069395 Haemosiderinuria Diseases 0.000 description 1
- 208000021727 Hantavirus hemorrhagic fever with renal syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000012925 Hemoglobin H disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 206010067265 Heterotaxia Diseases 0.000 description 1
- 208000002128 Heterotaxy Syndrome Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 1
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 1
- 101000984044 Homo sapiens LIM homeobox transcription factor 1-beta Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101001113490 Homo sapiens Poly(A)-specific ribonuclease PARN Proteins 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 208000020340 Immunotactoid glomerulopathy Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 201000002531 Karyomegalic interstitial nephritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
- 241000110847 Kochia Species 0.000 description 1
- 208000016028 Korean hemorrhagic fever Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 208000023768 LCAT deficiency Diseases 0.000 description 1
- 102100025457 LIM homeobox transcription factor 1-beta Human genes 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 206010027635 Milk-alkali syndrome Diseases 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010054837 Myolipoma Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000013233 NARP syndrome Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010058461 Orchitis noninfective Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000013234 Pearson syndrome Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 206010036072 Polyglandular autoimmune syndrome type I Diseases 0.000 description 1
- 206010036073 Polyglandular autoimmune syndrome type II Diseases 0.000 description 1
- 206010064115 Polyglandular autoimmune syndrome type III Diseases 0.000 description 1
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 description 1
- 206010063181 Propofol infusion syndrome Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010068513 Pulmonary renal syndrome Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000004035 RIDDLE syndrome Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- 201000003604 Renal agenesis Diseases 0.000 description 1
- 206010038366 Renal aneurysm Diseases 0.000 description 1
- 206010064655 Renal aplasia Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038422 Renal cortical necrosis Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 208000034955 Renal or urinary tract malformation Diseases 0.000 description 1
- 201000002982 Renal-hepatic-pancreatic dysplasia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000033368 Right sided atrial isomerism Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010062553 Scleroderma renal crisis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000012169 TAFRO syndrome Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010044668 Trigonitis Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010046530 Urinary bladder rupture Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000009788 Urogenital Tuberculosis Diseases 0.000 description 1
- 206010046696 Urogenital fistula Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008959 autophagy deficiency Effects 0.000 description 1
- 208000023351 autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome Diseases 0.000 description 1
- 201000003974 autosomal dominant hypocalcemia Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000025616 calcium-alkali syndrome Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000023124 congenital anomaly of kidney and urinary tract Diseases 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 208000006602 delta-Thalassemia Diseases 0.000 description 1
- 208000022401 dense deposit disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000030376 fibronectin glomerulopathy Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 235000020350 green smoothie Nutrition 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000003173 lipoprotein glomerulopathy Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 201000006790 nonsyndromic deafness Diseases 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010031129 orthostatic proteinuria Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 206010038351 renal abscess Diseases 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 201000005966 renal hypoplasia Diseases 0.000 description 1
- 208000012263 renal involvement Diseases 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000001958 right atrial isomerism Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000018019 sickle cell-hemoglobin c disease syndrome Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000133 toxic exposure Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580734P | 2017-11-02 | 2017-11-02 | |
| US62/580,734 | 2017-11-02 | ||
| US201862643061P | 2018-03-14 | 2018-03-14 | |
| US62/643,061 | 2018-03-14 | ||
| PCT/US2018/058955 WO2019090074A1 (en) | 2017-11-02 | 2018-11-02 | Modulators of the integrated stress pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501790A JP2021501790A (ja) | 2021-01-21 |
| JP2021501790A5 true JP2021501790A5 (https=) | 2021-12-09 |
| JP7335241B2 JP7335241B2 (ja) | 2023-08-29 |
Family
ID=64564979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524870A Active JP7335241B2 (ja) | 2017-11-02 | 2018-11-02 | 統合的ストレス経路の調節剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210393599A1 (https=) |
| EP (1) | EP3704089B1 (https=) |
| JP (1) | JP7335241B2 (https=) |
| KR (1) | KR20200092332A (https=) |
| CN (1) | CN112204006B (https=) |
| AU (1) | AU2018360855B2 (https=) |
| BR (1) | BR112020008817B8 (https=) |
| CA (1) | CA3080804A1 (https=) |
| IL (1) | IL274367B2 (https=) |
| MX (1) | MX2020004538A (https=) |
| SG (1) | SG11202004074TA (https=) |
| WO (1) | WO2019090074A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| US11478461B2 (en) | 2018-04-19 | 2022-10-25 | Merck Sharp & Dohme Llc | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI877863B (zh) | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3137213A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| AU2021213289A1 (en) | 2020-01-28 | 2022-07-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| JP2023546224A (ja) * | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CN116693529A (zh) * | 2023-06-09 | 2023-09-05 | 河南师范大学 | 一种2-氮杂环[2.2.2]辛烷类化合物的合成方法 |
| WO2024263972A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating uncommon cancers |
| WO2025153011A1 (zh) * | 2024-01-17 | 2025-07-24 | 北京泰德制药股份有限公司 | 血管紧张素ii受体拮抗剂及其用于治疗周围神经病理性疼痛的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US8476295B2 (en) * | 2009-12-14 | 2013-07-02 | Inspire | Bridged bicyclic RHO kinase inhibitor compounds, composition and use |
| AR084457A1 (es) * | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| CA2840060A1 (en) * | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| JP6806562B2 (ja) * | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| BR112017023764A2 (pt) * | 2015-05-05 | 2018-07-31 | Bayer Pharma AG | derivados de ciclohexano substituído por amido |
| WO2017035408A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
-
2018
- 2018-11-02 CA CA3080804A patent/CA3080804A1/en active Pending
- 2018-11-02 MX MX2020004538A patent/MX2020004538A/es unknown
- 2018-11-02 WO PCT/US2018/058955 patent/WO2019090074A1/en not_active Ceased
- 2018-11-02 EP EP18811983.8A patent/EP3704089B1/en active Active
- 2018-11-02 BR BR112020008817A patent/BR112020008817B8/pt active Search and Examination
- 2018-11-02 CN CN201880085147.1A patent/CN112204006B/zh active Active
- 2018-11-02 US US16/761,388 patent/US20210393599A1/en not_active Abandoned
- 2018-11-02 IL IL274367A patent/IL274367B2/en unknown
- 2018-11-02 SG SG11202004074TA patent/SG11202004074TA/en unknown
- 2018-11-02 JP JP2020524870A patent/JP7335241B2/ja active Active
- 2018-11-02 KR KR1020207015790A patent/KR20200092332A/ko not_active Ceased
- 2018-11-02 AU AU2018360855A patent/AU2018360855B2/en active Active
-
2023
- 2023-06-06 US US18/330,171 patent/US20240173307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501790A5 (https=) | ||
| JP2021501789A5 (https=) | ||
| JP2021501779A5 (https=) | ||
| JP2021501786A5 (https=) | ||
| JP2021501787A5 (https=) | ||
| JP2021501785A5 (https=) | ||
| JP2021501780A5 (https=) | ||
| JP2021501781A5 (https=) | ||
| JP2021501788A5 (https=) | ||
| JP2022530647A5 (https=) | ||
| RU2020117900A (ru) | Модуляторы интегрированного стресса | |
| JP2022504638A5 (https=) | ||
| RU2020117927A (ru) | Модуляторы интегрированного стресса | |
| JP6159484B2 (ja) | グレリンｏ−アシルトランスフェラーゼ阻害剤 | |
| JP2025504859A5 (https=) | ||
| TW201210599A (en) | Besylate salt of a BTK inhibitor | |
| JP2022501060A (ja) | 遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター | |
| TW202015693A (zh) | 治療pi3k 相關病症之給藥方案 | |
| JP2024536863A (ja) | イミダゾピリダジンｉｌ－１７阻害剤化合物 | |
| JP2025081327A (ja) | 異所性骨形成副作用の軽減で治療効果が増進した骨形成タンパク質－９、１０の変異体及びこれを含む薬学的組成物 | |
| US6294540B1 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| WO2023192642A2 (en) | Methods and compounds for modulating huntington's disease | |
| JP2025521602A (ja) | 炎症状態および自己免疫状態を処置するための方法および組成物 | |
| JP2022552019A5 (https=) | ||
| JP5881864B2 (ja) | 炭素環ヌクレオシドならびにその医薬的使用および組成物 |